

Exhibit A

--88. (Amend) The composition of claim 78, wherein the amount of the saponin is an amount between about [1] 10 ug and about [100] 200 ug.--

--94. (Amended) A method of [preventing or] treating a cancer in a subject which comprises administering to the subject an effective cancer [preventing or] treating amount of a composition which comprises:

- b) a conjugate of i) a GM2 or GD2 ganglioside derivative which comprises an unaltered oligosaccharide part and an altered ceramide portion, to ii) Keyhole Limpet Hemocyanin;
- b) a saponin derivable from the bark of a Quillaja saponaria Molina tree; and
- c) a pharmaceutically acceptable carrier;

the relative amounts of such conjugate and such saponin being effective to stimulate or enhance antibody production in the subject,
wherein in the conjugate the ganglioside derivative is conjugated to Keyhole Limpet Hemocyanin through a ceramide-derived carbon of the ganglioside derivative to Keyhole Limpet Hemocyanin, so as to thereby [prevent or] treat [a] the cancer in the subject.--

--95. (Amended) The method of claim [93 or] 94, wherein the cancer is of epithelial origin.--

--96. (Amended) The method of claim [93 or] 94, wherein the

Applicants: Philip Livingston and Friedhelm Hellings
Serial No.: 08/477,097
Filed: June 7, 1995
Page 25

cancer is of neuroectodermal origin.--

--98. (Amended) The method of [any one of claims 92-] claim 92 or 94, wherein the administering is effected at two or more sites.--

--99. (Amended) The method of claim [95] 98, wherein the administering is effected at three sites.--